Literature DB >> 21867581

Nationwide study of antipsychotic use among community-dwelling persons with Alzheimer's disease in Finland.

Marja-Liisa Laitinen1, J Simon Bell, Piia Lavikainen, Eija Lönnroos, Raimo Sulkava, Sirpa Hartikainen.   

Abstract

BACKGROUND: Antipsychotics continue to be widely used in the treatment of behavioral and psychological symptoms of dementia despite their limited effectiveness and well-known risks, including increased mortality. Our aim was to investigate the national pattern of antipsychotic use among community-dwelling persons with and without Alzheimer's disease (AD) in Finland.
METHODS: The Social Insurance Institution of Finland (SII) identified all persons with a verified diagnosis of AD in Finland on 31 December 2005. A control for each person with AD, matched in terms of age, sex and region of residence, was also identified. Data on reimbursed drug purchases in 2005 were extracted from the Finnish National Prescription Register. Conditional logistic regression analysis was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the use of antipsychotics.
RESULTS: The study population comprised 28,089 matched pairs of persons with and without AD (mean age 80.0 years, SD 6.8, 32.2% men). The annual prevalence of antipsychotic use was higher among persons with than without AD (22.1% vs. 4.4%, adjusted OR = 5.91; 95% CI 5.91-6.31). Among persons with AD, the prevalence of antipsychotic use was similar across all age groups. Of the antipsychotic users, 85.2% with AD and 51.3% without AD purchased second generation antipsychotics. Most antipsychotic prescriptions - 67.8% in the AD and 62.9% in the non-AD group - were generated in primary care situations.
CONCLUSION: One-fifth of persons with AD used antipsychotic drugs. Antipsychotic use was six times more prevalent among persons with AD than without AD. Most antipsychotics were prescribed by primary care physicians.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21867581     DOI: 10.1017/S1041610211001621

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  6 in total

1.  Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease research - the Medication use among persons with Alzheimer's disease (MEDALZ-2005) study.

Authors:  Anna-Maija Tolppanen; Heidi Taipale; Marjaana Koponen; Piia Lavikainen; Antti Tanskanen; Jari Tiihonen; Sirpa Hartikainen
Journal:  Clin Epidemiol       Date:  2013-08-07       Impact factor: 4.790

2.  Impact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer's disease: a national population cohort study.

Authors:  Danijela Gnjidic; Sarah N Hilmer; Sirpa Hartikainen; Anna-Maija Tolppanen; Heidi Taipale; Marjaana Koponen; J Simon Bell
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

3.  Prevalence and persistent use of psychotropic drugs in older adults receiving domiciliary care at baseline.

Authors:  Marie Turmo Lornstad; Marte Aarøen; Sverre Bergh; Jūratė Šaltytė Benth; Anne-Sofie Helvik
Journal:  BMC Geriatr       Date:  2019-04-25       Impact factor: 3.921

4.  Incident hip fractures among community dwelling persons with Alzheimer's disease in a Finnish nationwide register-based cohort.

Authors:  Anna-Maija Tolppanen; Piia Lavikainen; Hilkka Soininen; Sirpa Hartikainen
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

5.  Inequalities in receipt of mental and physical healthcare in people with dementia in the UK.

Authors:  Claudia Cooper; Rebecca Lodwick; Kate Walters; Rosalind Raine; Jill Manthorpe; Steve Iliffe; Irene Petersen
Journal:  Age Ageing       Date:  2017-05-01       Impact factor: 10.668

6.  Psychotropic drug prescription rates in primary care for people with dementia from recorded diagnosis onwards.

Authors:  Karlijn J Joling; Maud Ten Koppel; Hein P J van Hout; Bregje D Onwuteaka-Philipsen; Anneke L Francke; Robert A Verheij; Jos W R Twisk; Rob J van Marum
Journal:  Int J Geriatr Psychiatry       Date:  2020-10-16       Impact factor: 3.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.